Authors' reply [2]

Gut

Volumn 55, Issue 12, 2006, Pages 1819-1820

  Jover, R ^a   Castells, A ^b   Llor, X ^c   Andreu, M ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC ANTIMETABOLITE;

CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DNA METHYLATION; DRUG EFFICACY; HUMAN; LETTER; MISMATCH REPAIR; PRIORITY JOURNAL; PROGNOSIS; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; MICROSATELLITE INSTABILITY; NOTE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; MICROSATELLITE INSTABILITY;

EID: 33845431357     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.105627     Document Type: Letter

References (5)

1. Benatti P, Gafa R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11:8332-40.
2. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004;126:394-401.
3. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006;55:848-55.
4. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
5. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.